In the progress of allergy immunotherapy, numerous side effects may happen:
Subcutaneous immunotherapy requires that injections should be performed by trained personnel in clinical settings who are equipped to manage any possible systemic adverse reactions or anaphylaxis. Side effects are quite rare when allergy immunotherapy is performed according to proper safety recommendations. Allergy immunotherapy is contraindicated in patients with medical conditions that increase the risk of treatment-related severe Side effects, such as those with severe or poorly controlled asthma or significant cardiovascular diseases (eg, unstable angina, recent myocardial infarction, significant arrhythmia, and uncontrolled hypertension) and should be administered with caution to patients receiving b-blockers or angiotensin-converting enzyme inhibitors.Chronic nasal inflammatory responses and nasal polyps are not a contraindication for allergy immunotherapy.
Severe or uncontrolled asthma is the major independent risk factor for both nonfatal and fatal side effects and thus a major contraindication for both sublingual immunotherapy and subcutaneous immunotherapy. All patients undergoing allergy immunotherapy should be observed typically for at least 30 minutes after injection to ensure proper management of side effects.
There is no contraindication for allergy immunotherapy in patients with respiratory allergic diseases (allergic rhinoconjunctivitis and mild allergic asthma) associated with atopic dermatitis. Eczema is not worsened during or after allergy immunotherapy.
The treatment should be carefully regarded, so that many side effects can be avoided.